Open Access

Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma

  • Authors:
    • Lin He
    • Xuefei Cai
    • Shengtao Cheng
    • Hongzhong Zhou
    • Zhenzhen Zhang
    • Jihua Ren
    • Fang Ren
    • Qiuxia Yang
    • Nana Tao
    • Juan Chen
  • View Affiliations

  • Published online on: March 21, 2019     https://doi.org/10.3892/ol.2019.10174
  • Pages: 5030-5038
  • Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‑associated mortalities worldwide. The role of ornithine transcarbamylase (OTC) in HCC remains unclear. In the present study, the expression of OTC in HCC was analyzed based on datasets from the Gene Expression Omnibus database of the National Center for Biotechnology Information and further confirmed by immunohistochemistry, western blotting analysis and reverse transcription‑quantitative polymerase chain reaction assays on clinical samples and cell lines. Furthermore, the associations between OTC expression and clinicopathological parameters as well as clinical outcome, including the overall and disease‑free survival rates were analyzed. Finally, the effect of OTC on HCC cells was measured using proliferation, bromodeoxyuridine and colony‑formation assays. Lower OTC expression was observed in HCC cells and tissues compared with primary human hepatocytes. Further investigation demonstrated that low expression of OTC in HCC was associated with larger tumor size and advanced grade. A Kaplan‑Meier analysis revealed that patients with lower levels of OTC exhibited shorter overall and disease‑free survival times. Notably, OTC silencing with RNA interference facilitated cell proliferation in HCC SK‑Hep‑1 and Huh‑7 cells. However, overexpression of OTC led to inhibition of cell proliferation. In conclusion, the present study identified a novel role of OTC in HCC development, providing a potential novel therapeutic target for this disease.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

4 

Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Raza A and Sood GK: Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol. 20:4115–4127. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Yu W, Lin Y, Yao J, Huang W, Lei Q, Xiong Y, Zhao S and Guan KL: Lysine 88 acetylation negatively regulates ornithine carbamoyltransferase activity in response to nutrient signals. J Biol Chem. 284:13669–13675. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Auron A and Brophy PD: Hyperammonemia in review: Pathophysiology, diagnosis, and treatment. Pediatr Nephrol. 27:207–222. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Helman G, Pacheco-Colón I and Gropman AL: The urea cycle disorders. Semin Neurol. 34:341–349. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Capistrano-Estrada S, Marsden DL, Nyhan WL, Newbury RO, Krous HF and Tuchman M: Histopathological findings in a male with late-onset ornithine transcarbamylase deficiency. Pediatr Pathol. 14:235–243. 1994. View Article : Google Scholar : PubMed/NCBI

10 

El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Wilson JM, Shchelochkov OA, Gallagher RC and Batshaw ML: Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab. 105:263–265. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Wang L, Bell P, Morizono H, He Z, Pumbo E, Yu H, White J, Batshaw ML and Wilson JM: AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Mol Genet Metab. 120:299–305. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Cuccurullo V and Mansi L: AJCC cancer staging handbook: From the AJCC cancer staging manual (7th edition). Eur J Nucl Med Mol Imaging. 38:408. 2011. View Article : Google Scholar

14 

Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI

15 

Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR and Wang XW: Oncogenic activation of the RNA binding protein NELFE and MYC signaling in hepatocellular carcinoma. Cancer Cell. 32:101–114 e08. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Tommasi S, Zheng A, Weninger A, Bates SE, Li XA, Wu X, Hollstein M and Besaratinia A: Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res. 41:182–195. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Ramboer E, De Craene B, De Kock J, Vanhaecke T, Berx G, Rogiers V and Vinken M: Strategies for immortalization of primary hepatocytes. J Hepatol. 61:925–943. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Mori M, Miura S, Morita T, Takiguchi M and Tatibana M: Ornithine transcarbamylase in liver mitochondria. Mol Cell Biochem. 49:97–111. 1982. View Article : Google Scholar : PubMed/NCBI

21 

Liu H, Dong H, Robertson K and Liu C: DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol. 178:652–661. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, Shortreed MR, Prolla T, Markley JL, Smith LM, et al: Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell. 41:139–149. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Song CL, Tang H, Ran LK, Ko BC, Zhang ZZ, Chen X, Ren JH, Tao NN, Li WY, Huang AL and Chen J: Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway. Oncogene. 35:631–641. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Liu Q, Ding MH, Zhang R, Chen HX, Zhou XX, Xu HF, Chen H and Peng KL: Study on mechanism of thyroid cytotoxicity of ammonium perchlorate. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 31:418–421. 2013.(In Chinese). PubMed/NCBI

25 

Luo C, Shen G, Liu N, Gong F, Wei X, Yao S, Liu D, Teng X, Ye N, Zhang N, et al: Ammonia drives dendritic cells into dysfunction. J Immunol. 193:1080–1089. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Wang Q, Wang Y, Yu Z, Li D, Jia B, Li J, Guan K, Zhou Y, Chen Y and Kan Q: Ammonia-induced energy disorders interfere with bilirubin metabolism in hepatocytes. Arch Biochem Biophys. 555-556:16–22. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Xu Y, Wang N, Ding Y, Wang C, Yu Y, Liu S, Wang X and Li Z: Ammonium chloride enhances cisplatin cytotoxicity through DNA double-strand breaks in human cervical cancer cells. Oncol Rep. 30:1195–1200. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et al: Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 496:101–105. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Díaz-Muñoz M and Hernández-Muñoz R: Molecular and biochemical features of the mitochondrial enzyme ornithine transcarbamylase: A possible new role as a signaling factor. Curr Med Chem. 17:2253–2260. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
He, L., Cai, X., Cheng, S., Zhou, H., Zhang, Z., Ren, J. ... Chen, J. (2019). Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncology Letters, 17, 5030-5038. https://doi.org/10.3892/ol.2019.10174
MLA
He, L., Cai, X., Cheng, S., Zhou, H., Zhang, Z., Ren, J., Ren, F., Yang, Q., Tao, N., Chen, J."Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma". Oncology Letters 17.6 (2019): 5030-5038.
Chicago
He, L., Cai, X., Cheng, S., Zhou, H., Zhang, Z., Ren, J., Ren, F., Yang, Q., Tao, N., Chen, J."Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma". Oncology Letters 17, no. 6 (2019): 5030-5038. https://doi.org/10.3892/ol.2019.10174